Table 3.

Selected studies of allo-HCT in BPDCN

Publication	Study	N	Remission status at allo-HCT (n)	Donor type (n)	Regimen intensity (n)	Outcomes
Roos-Weil et al14	EBMT	34	CR1 = 19 >CR1 = 15	MSD = 11 MUD = 23	MAC = 25 RIC/NMA = 9	3-y OS: 41% 3-y NRM: 30% 3-y relapse: 32%
Kharfan-Dabaja et al12	North America	37	CR1 = 28 >CR1 = 9	MSD=16 MUD = 12 Other: 9∗	MAC = 20 RIC/NMA = 17	3-y OS: 58% 1-y NRM: 25% 3-y relapse: 10%
Bashir et al13	MDACC	17	CR1 = 10 >CR1 = 7	MSD = 5 MUD = 5 Other: 7†	MAC = 13 RIC/NMA = 4	5-y OS: 40% 1-y NRM: 29% 5-y relapse: 22%
Murthy et al (this study)	CIBMTR	164	CR = 121 >CR1 = 43	MSD = 41 MUD = 65 Other = 58‡	MAC = 84 RIC = 80	5-y OS: 51.2% 5-y NRM: 23.3% 5-y relapse: 32.2%

MDACC, MD Anderson Cancer Center; MSD, matched sibling donor; MUD, matched unrelated donor.

^∗Umbilical cord blood = 4, haploidentical = 3, mismatch unrelated = 2.

^†Umbilical cord blood = 3, haploidentical = 4.

^‡Umbilical cord blood = 11, haploidentical = 28, mismatch unrelated = 10, multidonor = 1, unknown = 8.